Table 10.
Previous reports regarding the association between TP53 variation status and IHC expression of p53
| Study | Cancer type | Case number | Clone | Sensitivity | Specificity | Accuracy |
|---|---|---|---|---|---|---|
| Kobel et al., 2016 [15] | Ovarian carcinoma | 168 | DO-7 | 96% | 100% | 98% |
| Kortekaas et al., 2020 | Vulvar carcinoma | 59 | DO-7 | 95.3% | 100% | 96.6% |
| Singh et al., 2020 | Endometrial carcinoma | 207 | DO-7 | 90.82% | 94.29% | 92.26% |
| Yu et al., 2021 | Gastric carcinoma | 42 | DO-7 | 100% | 77.78% | 93.75% |
| MX008 | 95.65% | 100% | 96.88% | |||
| BP53–12 | 95.65% | 88.89% | 93.75% | |||
| SP5 | 100% | 100% | 100% | |||
| Present study | Colorectal carcinoma | 204 | DO-7 | 87.2% | 61.8% | 80.4% |
| Bp53–11 | 92.6% | 69.1% | 86.3% | |||
| SP5 | 91.9% | 76.4% | 87.7% |